Nan Fung Group Holdings LTD Tcr2 Therapeutics Inc. Transaction History

Nan Fung Group Holdings LTD

  • $103 Million
  • Q3 2024

Shares

1 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2022

May 13, 2022
BUY
$2.4 - $4.71 $46,404 - $91,067
19,335 New
19,335 $53,000

About TCR2 THERAPEUTICS INC.

TCRR Quotes by TradingView
  • Ticker TCRR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 38,606,400
  • Description
  • TCR2 Therapeutics Inc., a clinical-stage immunotherapy company, focuses on developing novel T cell receptor (TCR) therapies for patients suffering from cancer. The company's lead product candidates include gavo-cel, a mono TCR Fusion Construct T cells (TRuC-T cells) targeting mesothelin positive solid tumors, which is in phase I/II clinical tria...
More about TCRR
Track This Portfolio

Track Nan Fung Group Holdings LTD Portfolio

Follow Nan Fung Group Holdings LTD and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Nan Fung Group Holdings LTD, based on Form 13F filings with the SEC.

News

Stay updated on Nan Fung Group Holdings LTD with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email